NCT03060603

Proliferative Effects of Erythropoietin on Human Endometrium

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 14 (actual)
• Sponsor: Fatih Sultan Mehmet Training and Research Hospital · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study to assess the proliferative effects of erythropoetin on human endometrium tissue by measuring the endometrial thickness, uterine artery and subendometrial blood flow in postmenopausal women.

Detailed description

20 postmenopausal women who are planned to treat with erythropoietin alpha for their renal conditions will be included to the study. Sample size was calculated with proper power analysis with accepting the difference of 1 mm in endometrial thickness as a significant change. After the informed consent, endometrial thickness (mm), uterine artery and subendometrial blood flow by doppler ultrasonography (RI, S/D) will be measured. Same measurements will be repeated on the 3rd day and 30th day. Patients' age, BMI, co-morbidities, administered erythropoietin doses will be noted. No adverse effect is expected with regard to the ultrasonographic examination. Date of the patients who do not attend for the appointments for repetitive examinations and uninterpretable doppler variables due to the atrophic uterus will be noted as the missing data and will be excluded from the study. Proper statistical analysis will be done.

Conditions

• Anemia
• Endometrial Diseases

Interventions

Type	Name	Description
DRUG	Erythropoietin	Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.

Timeline

• Start date: 2017-02-23
• Primary completion: 2017-12-29
• Completion: 2018-01-15
• First posted: 2017-02-23
• Last updated: 2018-01-23

Locations

1 site across 1 country: Turkey (Türkiye)